Hospital-Acquired Pneumonia Is Life Or Death, FDA Says; Recommends All-Cause Mortality As Sole Primary Endpoint
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Rigorous enrollment criteria and strict endpoints characterize FDA's new draft guidance on developing drugs for hospital-acquired and ventilator-associated bacterial pneumonia, even compared with the agency's recent draft guidance on developing drugs for community-acquired bacterial pneumonia.
You may also be interested in...
Special Protocol Assessments Get Special Focus In Antibiotic Guidance
FDA's final guidance on non-inferiority studies in antibiotic drug development is little changed from the 2007 draft version, but provides further clarity for sponsors working under an SPA.
FDA's Pending HAP/VAP Guidance Could Further Dampen Antibiotic Drug Development
FDA's pending guidance on clinical trials for antibiotics to treat hospital- and ventilator-acquired pneumonia can't help but add a measure of stability to the uncertain regulatory environment in the field, but stakeholders fear that when the clouds part, the view will be of a very high bar.
Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: